# Evaluation of Tolerability of Adjuvant Cisplatin/Docetaxel in Completely Resected Stage IB/II Non-Small Cell Lung Cancer

> **NCT00434668** · PHASE2 · COMPLETED · sponsor: **University Hospital, Antwerp** · enrollment: 99 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** cisplatin/docetaxel
- **DRUG:** cisplatin/vinorelbine

## Key facts

- **NCT ID:** NCT00434668
- **Lead sponsor:** University Hospital, Antwerp
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2010-09
- **Final completion:** 2010-11
- **Target enrollment:** 99 (ESTIMATED)
- **Last updated:** 2010-11-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00434668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00434668, "Evaluation of Tolerability of Adjuvant Cisplatin/Docetaxel in Completely Resected Stage IB/II Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00434668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*